Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

11 results about "Teichoic acid" patented technology

Teichoic acids (cf. Greek τεῖχος, teīkhos, "wall", to be specific a fortification wall, as opposed to τοῖχος, toīkhos, a regular wall) are bacterial copolymers of glycerol phosphate or ribitol phosphate and carbohydrates linked via phosphodiester bonds.

Postbiotic of weizmannia coagulans, and preparation method therefor and use thereof

Provided are a postbiotic of Weizmannia coagulans, and a preparation method therefor, and a use thereof. The postbiotic comprises inactivated bacteria and / or lipoteichoic acid. The postbiotic can enhance the phagocytosis activity of macrophages, the cytokine and NO secretion ability of macrophages, and the expression levels of immune-function-related genes and proteins, and has an effect of inducing human PBMC cells to kill cancer cells.
Owner:COREE CO LTD

Lactobacillus paragasseri and application thereof

The present application relates to the field of microorganism, discloses a lactobacillus paragasseri and application thereof. The lactobacillus paragasseri with the preservation number CGMCC No.36335 provided by the present application can metabolize multiple non-digestible carbohydrates, especially xylo-oligosaccharides, resistant starch, arabinose and mucin, and realize growth and reproduction by taking these substances as the only carbon source; can relieve constipation, and has the application prospect of preparing preparations for defecation; can produce high-yield lipoteichoic acid, and has the application value for industrial production of lipoteichoic acid.
Owner:COFCO NUTRITION AND HEALTH RESEARCH INSTITUTE CO LTD +1

Use of teichoic acid derived from animal bifidobacterium in preparation of food and medicine for relieving liver injury

PendingCN122499203ABiotechnologyMicrobiology
This invention discloses the application of teichoic acid derived from Bifidobacterium animalis in the preparation of foods and pharmaceuticals that alleviate liver damage. The teichoic acid is extracted from Bifidobacterium animalis, including the following steps: extracting teichoic acid from Bifidobacterium animalis subsp. lactis YSJ-02. The Bifidobacterium animalis subsp. lactis YSJ-02 (… Bifidobacterium animalis subsp. lactis YSJ-02 is deposited at the China Center for Type Culture Collection (CCTCC), accession number CCTCC NO: M 20253030, address: Wuhan University, Wuhan, China. This total extract of teichoic acid can effectively alleviate liver damage caused by various factors.
Owner:THE FIRST AFFILIATED HOSPITAL ZHEJIANG UNIV COLLEGE OF MEDICINE

A type ii lipoteichoic acid and a method for preparing the same

The application belongs to the technical field of biological medicine and chemical synthesis, and particularly relates to a type II lipoteichoic acid and a preparation method thereof. The type II lipoteichoic acid is selected from a compound shown in the following formula I, wherein X is independently selected from H or a fatty acyl group. The application adopts a pre-activated O-glycosyl trichloroacetimidate donor glycosylation method to sequentially construct different types of alpha-configuration glycoside bonds in the molecule, and prepares a lipoteichoic acid skeleton unit through coupling of phosphate esters. The method has the advantages of high conversion rate, low cost, large-scale preparation and the like, and therefore has good practical application value.
Owner:SHANDONG UNIV

Peptidoglycan (PGN) aptamers and associated methods

Described are a number of aptamers that are specific to bind with peptidoglycan (“PGN”) with specificity over counter-targets lipopolysaccharides (“LPS”) and lipoteichoic acid (“LTA”), and associated methods.
Owner:FRESENIUS MEDICAL CARE HOLDINGS INC

Lactobacillus paragasseri and application thereof

The invention relates to the field of microorganisms, and discloses lactobacillus paragasseri and application thereof. The lactobacillus paraggaricus with the preservation number of CGMCC (China General Microbiological Culture Collection Center) No.36335 provided by the invention can metabolize various non-digestible carbohydrates, especially xylooligosaccharide, resistant starch, arabinose and mucoprotein, and the substances are used as a unique carbon source to realize growth and reproduction; the composition can relieve constipation and has an application prospect of preparing a preparation for relaxing the bowels; the method can realize high yield of lipoteichoic acid, and has an application value for industrial production of lipoteichoic acid.
Owner:COFCO NUTRITION AND HEALTH RESEARCH INSTITUTE CO LTD +1

Use of lipoteichoic acid (LTA) and / or lipopolysaccharide (LPS) positive extracellular vesicles in plasma

The present application belongs to the field of medicine and health, and relates to the use of lipoteichoic acid (LTA) and / or lipopolysaccharide (LPS) positive extracellular vesicles in plasma in the detection of bacterial inflammation and / or bacteremia. Specifically, the present application provides an in vitro method for detecting bacterial inflammation and / or bacteremia, comprising the following steps: providing a sample to be tested from a subject; isolating extracellular vesicles from the sample to be tested; detecting the level of LPS positive extracellular vesicles (LPS + EVs) and / or the level of LTA positive extracellular vesicles (LTA + EVs); if the levels of LPS + EVs and / or LTA + EVs increase, it indicates that the subject has bacterial inflammation and / or bacteremia.
Owner:RENJI HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE

Rifamycin analogs and antibody-drug conjugates thereof

The disclosure relates to rifamycin analog compounds, intermediates and precursors thereof, and pharmaceutical compositions capable of inhibiting bacterial growth (e.g., S. aureus growth) and treating bacterial infections (e.g., S. aureus infections). The disclosure further relates to antibody-drug conjugates of rifamycin analog compounds and antibodies, for example, antibodies specific for infectious disease-related targets such as membrane glycoprotein receptor (MSR1), wall teichoic acids (WTA) or Protein A, and methods of use thereof to inhibit bacterial growth and treat bacterial infections.
Owner:REGENERON PHARMACEUTICALS INC

Lipoteichoic acid from bacillus subtilis and use thereof for maintaining the intestinal health of bullfrogs

The present application relates to a kind of bacillus subtilis lipoteichoic acid and its extraction method and application, the extraction method of bacillus subtilis lipoteichoic acid includes: preparation chromatographic column, obtain packed chromatographic column standby;Bacillus subtilis bacterial liquid is added to n-butanol, after stirring uniformly, centrifugal, take middle lower layer water phase, freeze-drying is obtained by vacuum freeze-drying machine with lipoteichoic acid crude extract;The lipoteichoic acid crude extract is dissolved in the equilibrium buffer solution, after centrifugal processing, take supernatant, the supernatant is loaded into the packed chromatographic column, after the supernatant is all entered into the packed chromatographic column, eluent is added to the packed chromatographic column by peristaltic pump, filtrate is collected, and the bacillus subtilis lipoteichoic acid obtained after freeze-drying of the filtrate is obtained.The bacillus subtilis lipoteichoic acid is added to high soybean meal protein feed, can maintain the intestinal health of feeding high soybean meal protein feed bullfrog, improve the feeding effect, with excellent application prospect.
Owner:JIMEI UNIV

Antimicrobial peptide nanonets and methods of use thereof

Disclosed are synthetic β-hairpin antimicrobial peptides (AMPs) of 13–15 amino acids and compositions thereof comprising a pathogen-recognition hairpin turn (e.g., LTA or VpPA) and β-sheet-forming side strands that self-assemble into nanonets and interwoven nanofibers upon contact with bacterial lipoteichoic acid or lipopolysaccharide, or fungal cell wall / membrane components. The peptides trap, immobilize, and kill bacteria and 0 fungi, including antibiotic-resistant strains, reduce motility, and neutralize endotoxin. Coated substrates and medical devices bearing covalently conjugated AMPs prevent or reduce biofilm formation, sustain antifouling activity, and attenuate inflammatory cytokines. Methods of treating infections and immune-related diseases, and kits comprising AMP-coated substrates or medical devices are also provided.
Owner:NATIONAL UNIVERSITY OF SINGAPORE

Chitosan grafting modified bio-based nylon material, and preparation method and application thereof

The application belongs to the technical field of polymer material modification, and provides a chitosan grafted modified bio-based nylon material, a preparation method and application thereof.The preparation method comprises the following steps: mixing bio-based nylon salt, water, a catalyst and chitosan quaternary ammonium salt under a protective atmosphere, sequentially performing pre-polymerization and final polymerization to obtain the chitosan grafted modified bio-based nylon material.The chitosan quaternary ammonium salt is selected to react with the bio-based nylon salt, so that the number of positive charges on the surface of the original polyamide is increased, a large number of positive charges can promote the flocculation of the polyamide and the proteins, teichoic acid, lipopolysaccharide and the like with negative charges on the surface of the bacterial cell, and then the osmotic barrier effect of the cytoplasmic membrane is destroyed, the integrity of the bacterial cell is destroyed, and the nutrients are lost, so that the intrinsic antibacterial effect is achieved.The chitosan grafted modified bio-based nylon material has excellent antibacterial performance, mechanical properties and high-temperature resistance.
Owner:INSTITUTE OF PROCESS ENGINEERING CHINESE ACADEMY OF SCIENCES +1